Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Current Assets (2016 - 2025)

Heron Therapeutics' Current Assets history spans 14 years, with the latest figure at $238.1 million for Q4 2025.

  • For Q4 2025, Current Assets rose 13.9% year-over-year to $238.1 million; the TTM value through Dec 2025 reached $238.1 million, up 13.9%, while the annual FY2025 figure was $238.1 million, 13.9% up from the prior year.
  • Current Assets reached $238.1 million in Q4 2025 per HRTX's latest filing, up from $229.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $366.8 million in Q2 2021 to a low of $165.3 million in Q2 2023.
  • Average Current Assets over 5 years is $222.7 million, with a median of $210.0 million recorded in 2024.
  • Peak YoY movement for Current Assets: plummeted 47.06% in 2022, then increased 17.53% in 2025.
  • A 5-year view of Current Assets shows it stood at $254.4 million in 2021, then dropped by 19.25% to $205.4 million in 2022, then fell by 8.11% to $188.8 million in 2023, then grew by 10.72% to $209.0 million in 2024, then rose by 13.9% to $238.1 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Current Assets are $238.1 million (Q4 2025), $229.4 million (Q3 2025), and $210.9 million (Q2 2025).